Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NSCLC × Gefitinib × Clear all

Phase

Phase 2/3 2 Phase NA 1 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 26 Lung Neoplasms 6 Neoplasms 3 Adenocarcinoma of Lung 3 Neoplasm Metastasis 2 Brain Neoplasms 2 Adenocarcinoma, Bronchiolo-Alveolar 2 Urinary Bladder Neoplasms 1 Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 NSCLC 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Head and Neck Neoplasms 1 EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1 Carcinoma 1 Adenocarcinoma 1

Interventions

osimertinib 3 Vinorelbine 3 Pemetrexed 3 Cisplatin 3 Carboplatin 3 Gemcitabine 2 Docetaxel 2 CP protocol 2 pembrolizumab 1 aumolertinib 1 Taxes 1 Paclitaxel 1 HMPL-013 1 HM781-36B 1 Gefitinib 1 Erlotinib Hydrochloride 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03656393 2018-09-04

RCTACSCNSCLC

Shenzhen People's Hospital

Phase 3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡